Intradermal or intravenous administration typically requires 1–2 hours; patients often resume light activity same-day. Mild localised inflammation or fatigue within 24–48 hours is commonly reported. No extended downtime is expected. However, onset of any symptomatic benefit is gradual, unfolding over weeks rather than days. Immediate post-procedure monitoring protocols differ between clinics.
Approximately 10 registered trials are investigating stem cell and exosome therapies for menopause-related symptoms. A 2023 small-scale study of placental MSCs reported subjective improvement in hot flush frequency in 70% of participants over 12 weeks, though follow-up assessments remain limited. Exosome trials have focused on anti-inflammatory signalling rather than direct hormone replacement. No large multicentre randomised controlled trials have yet demonstrated safety or efficacy comparable to hormone therapy, and recruitment for new menopause-focused stem cell studies has stalled. Evidence remains preliminary and largely mechanistic.
Am I a candidate? → · Menopause & Hormonal Health: full overview → · Menopause & Hormonal Health cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Dmytro Stoyanov (Urologist · 31+ yrs clinical practice) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite